Key Takeaways
- FDA approval creates availability; access determines whether patients can receive therapy.
- Payer evidence often takes significant time to develop—waiting until launch leaves few options.
- The patient journey continues after the prescription through benefit verification, authorization and specialty pharmacy.
- Coverage creates opportunity; commercial execution still must translate opportunity into treatment initiation.
FDA approval is a defining milestone. Commercially, however, approval answers only one question: Can the product be made available?
It does not answer whether patients can realistically receive it. That distinction makes early Market Access planning essential.
PharmaKonsult approaches this as commercial market access strategy—integrating access into commercialization leadership, not replacing specialist payer analytics.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
